Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zalcitabine · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Zidovudine | DRUG | - |
| Zalcitabine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. * CD4 count 100 - 500 cells/mm3.
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
Zalcitabine is an investigational small molecule studied for the treatment of HIV Infections. It was evaluated in clinical trials both as a single agent and in combination regimens with zidovudine (AZT), including in patients with AIDS or advanced ARC who had previously shown intolerance to zidovudine.
Zalcitabine was developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche sponsored the clinical trial program evaluating the drug in HIV Infections, including studies of Zalcitabine alone and in combination with zidovudine.
Zalcitabine reached Phase 3 clinical development for HIV Infections. Its Phase 3 trial, NCT00002117, was a randomized, open-label study of alternative treatment combinations of dideoxycytidine (ddC) and zidovudine (AZT) in patients with HIV infection. Zalcitabine is investigational and is not an approved therapy based on this development record.
Zalcitabine was studied in two completed HIV Infection trials. NCT00002117 was a Phase 3 randomized, open-label study of ddC and AZT combinations with 528 patients. NCT00002265 was a Phase 2 open-label, multicenter study of dideoxycytidine in patients with AIDS or advanced ARC who were intolerant to zidovudine.
Yes. Zalcitabine is also known as dideoxycytidine, abbreviated ddC, and was marketed under the brand name HIVID. These names refer to the same small molecule, which was studied in HIV Infections both as monotherapy and in combination with zidovudine (AZT).
The Zalcitabine clinical program enrolled 528 patients in total, all in the Phase 3 trial NCT00002117, which compared alternative combinations of dideoxycytidine (ddC) and zidovudine (AZT) in patients with HIV infection. The Phase 2 study NCT00002265 did not report an enrollment figure.